Compare STEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | VERA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | STEL | VERA |
|---|---|---|
| Price | $30.73 | $48.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $31.33 | ★ $76.60 |
| AVG Volume (30 Days) | 266.7K | ★ 1.5M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $416,539,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.13 | $18.53 |
| 52 Week High | $32.74 | $56.05 |
| Indicator | STEL | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 59.89 |
| Support Level | $31.16 | $47.22 |
| Resistance Level | $31.14 | $56.05 |
| Average True Range (ATR) | 0.60 | 2.51 |
| MACD | -0.19 | -0.69 |
| Stochastic Oscillator | 10.80 | 32.26 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc.; and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.